Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026
August 01, 2022 05:13 ET
|
Research and Markets
Dublin, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022, By Derived Cell Type, By Application, By End-User" report has been added to...
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Surging Number of Preclinical and Physician-led Studies and Formal Clinical Trials Presents Opportunities
July 11, 2022 07:33 ET
|
Research and Markets
Dublin, July 11, 2022 (GLOBE NEWSWIRE) -- The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022" report has been added to ResearchAndMarkets.com's offering. Since the discovery of...
Global Stem Cell Assays Market Projected to Reach $4.5 Billion by 2027
July 06, 2022 07:18 ET
|
Research and Markets
Dublin, July 06, 2022 (GLOBE NEWSWIRE) -- The "Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product &...
Global Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis & Forecasts, 2017-2020 & 2021-2028
November 16, 2021 06:03 ET
|
Research and Markets
Dublin, Nov. 16, 2021 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report By Application (Manufacturing, Academic Research, Drug...
Global Stromal Vascular Fraction Market Report 2021: Market to Reach $97.6 Million by 2026 - Extensive Therapeutic Scope Set to Stimulate Growth of the Market
November 11, 2021 04:18 ET
|
Research and Markets
Dublin, Nov. 11, 2021 (GLOBE NEWSWIRE) -- The "Stromal Vascular Fraction - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Stromal...
Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer
October 12, 2021 12:24 ET
|
Cytovia Therapeutics
AVENTURA, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc. (“Cytovia”), a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen...
Bone Therapeutics signe un partenariat de recherche avec Implant Therapeutics pour garantir son accès à des Cellules Souches Pluripotentes induites (CSPi)
September 28, 2021 01:00 ET
|
Bone Therapeutics SA
INFORMATION REGLEMENTEE Bone Therapeutics bénéficiera de l’expertise d’Implant Therapeutics et pourra accéder à des lignées cellulaires Souches Pluripotentes induites (SPi), incluant des...
Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)
September 28, 2021 01:00 ET
|
Bone Therapeutics SA
REGULATED INFORMATION Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise iPSC technology allows for the...
Global $4.54 Bn Induced Pluripotent Stem Cell (iPSC) Markets, 2021-2025 & 2030
September 14, 2021 05:53 ET
|
Research and Markets
Dublin, Sept. 14, 2021 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
The Worldwide Stem Cell Manufacturing Industry is Expected to Reach $18 Billion by 2026 at a CAGR of 9.4% from 2021
May 31, 2021 07:03 ET
|
Research and Markets
Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Manufacturing Market by Product (Consumables, Instrument, HSCs, MSCs, iPSCs, ESCs), Application (Research, Clinical (Autologous,...